Kornimate/medical-research-clean huggingface dataset:
platelet indices in decompensated post hepatitic liver cirrhosis

Conditions: MPV; PDW

Summary: the aim of the present work is to study platelet indices ( platelet count - mean platelet volume - platelet distribution width ) as noninvasive predictors in decompensated post hepatitic liver cirrhosis .

cirrhosis is an advanced liver disease characterized by fibrosis and alteration in hepatic architecture with the development of structurally anomalous nodules . ascites is a condition in which pathological collection of fluid occurs within the peritoneal cavity mainly because of portal hypertension. it is a major complication of liver cirrhosis, the appearance of ascites in cirrhotic patients indicates a poor prognosis , spontaneous bacterial peritonitis is a severe infection, commonly occurring in cirrhotic ascitic patients. platelets are attributed to preserve hemostasis. yet, recently, there has been growing recognition that they also play an essential role in inflammatory and immune response. platelets release prothrombotic and proinflammatory agents and participate in the induction and advancement of vascular and inflammatory disorders . larger-sized platelets contain many granules, and are therefore more efficient in their hemostatic and proinflammatory actions . this is why the mean platelet volume (mpv) and platelet distribution width (pdw) are worth considering as potential tests for platelet function and activation . the mpv and pwd can be calculated using almost all automated hematology analyzers. the mpv indicates the average platelet size in femtoliters. the pdw, reflecting homogeneity of platelet size, is calculated from the mpv by the equation (sd of platelet volume divided by mpv×100) or the distribution width at 20% frequency .

Eligibility criteria:
inclusion criteria: * post hepatitic liver cirrhotic patients exclusion criteria: * renal failure patients * pregnents * diabetic patients * patients with bone marrow disorders specially platelet disorders * patient with other cause of liver cirrhosis
a clinical study to evaluate the tolerability and pharmacokinetics of tqb3811 tablets in patients with advanced malignant tumors

Conditions: Solid Tumor

Summary: tqb3811 tablet is a second-generation tropomyosin receptor kinase (trk) inhibitor that selectively inhibits the kinase activity of trka, trkb, and trkc, and also selectively inhibits the kinase activity of trka, trkb, and trkc that produce secondary drug-resistant mutations.


Eligibility criteria:
inclusion criteria: * patients with advanced malignancy diagnosed histologically and/or cytologically, who have failed standard treatment or are unable to receive standard treatment or have no effective treatment. * age: 18\~75 years old. * women of childbearing age must be negative for serum or urine hcg within 7 days prior to study enrollment and must be non-lactating; patients should agree to use contraception during the study period and for 6 months after the study period. * eastern cooperative oncology group (ecog) performance status of 0 to 1; life expectancy ≥ 3 months. * patients voluntarily joined the study and signed the informed consent, showing good compliance. exclusion criteria: * patients has had or is currently having other malignant tumors within 3 years. * patients have multiple factors that affect their oral medication (such as inability to swallow, chronic diarrhea, and intestinal obstruction). * the patient had unmitigated toxic reactions due to any prior treatment. * patients underwent major surgical treatment, open biopsy, or significant traumatic injury within 4 weeks prior to the start of study treatment. * patients have long-term unhealed wounds or fractures. * the patient had experienced an arterial/venous thrombosis event in the past 6 months, such as a cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep venous thrombosis, and pulmonary embolism. * the patient has a history of psychotropic drug abuse and cannot quit or has mental disorders. * patients are taking cytochrome p450 3a (cyp3a) inhibitors or inducers. * patients have uncontrolled pleural effusion, pericardial effusion, or ascites that still require repeated drainage. * patients with brain metastases with symptoms or control of symptoms for less than 2 weeks. * the patients were currently breastfeeding or planned to breastfeed during the study period. * patients who, in the investigator's judgment, have a comorbidity that seriously endangers patient safety or interferes with study completion, or who are considered unsuitable for inclusion for other reasons
allograft transplantation in the treatment of osteoarthritis of the metatarsophalangeal (mtp) joint of the great toe

Conditions: Osteoarthritis

Summary: using the concept of an implant acting as a spacer and stabilizer, the proposed study will evaluate the use of allograft knee meniscus in the treatment of mtp joint osteoarthritis of the great toe.

a variety of surgical procedures have been developed for the treatment of mtp joint osteoarthritis of the great toe. using the concept of an implant acting as a spacer and stabilizer, the proposed study will evaluate the use of allograft knee meniscus in the treatment of mtp joint osteoarthritis of the great toe. patients will be evaluated for pain and range of motion at 3-months, 6-months, 1-year, 2-years, 3-years, 4-years, and 5-years postoperatively or until allograft failure. stability of the allograft will be evaluated by the surgeon at these time points per radiographic imaging.

Eligibility criteria:
inclusion criteria: * symptomatic of stage 3 osteoarthritis of the great toe * symptoms recalcitrant to nonoperative management as determined clinically by the principal investigator exclusion criteria: * diabetes mellitus * kidney insufficiency * oa in the adjacent joints * malignancy with in the past 10 yrs * minors (\< 18 yrs of age) * pregnant women and fetus * mentally disabled or cognitively impaired individuals

Keywords: allograft great toe
demographic , clinicopathological characteristics and survival of breast cancer

Conditions: Breast Carcinoma

Summary: the investigators will retrospectively study the demographic , clinicopathological characteristics and survival of breast cancer patients admitted to assiut university hospital from the year 2015 to 2019

breast cancer is one of the most common malignancies in females, which is the second leading cause of cancer death throughout the world after lung cancer . the incidence of breast cancer has been increasing over the past decades , especially in young women (≤ 35 years old). there is approximately 182,000 women with breast neoplasm annually in the united states, accounting for about 26% of all incident cancers among women. in asia, the morbidity rate is as high as 9.5%-12% . even worse in china, the average onset age of breast cancer might be 8-10 years younger than that in western countries which account for upto 4% in total breast cancer patients . in egypt, breast cancer is the commonest type of female malignancy represented about 38.8% among common cancer sites in females.although the unclear etiology of the majority of breast cancer, but there are numerous risk factors for the disease. screening and early detection when combined with adequate, efficient treatment is considered the hope for a reduction of mortality in breast cancer as postulated by world health organization (who).

Eligibility criteria:
inclusion criteria: * all histologically confirmed and documented patients with invasive ductal or lobular carcinoma of the breast attending at assiut university hospital from year 2015 to 2019. exclusion criteria: * • patients who previously received treatment outside assiut university hospital. * a serious un controlled concomitant disease that would contraindicate with use of systemic treatment. .
study of 0416 ointment in the treatment of atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the aim of this trial is to assess the efficacy of 0416 ointment in the treatment of atopic dermatitis. treatment medication will be administered as follows: apply a thin layer of ointment to affected skin areas twice daily and rub in gently and completely. study medication will be applied twice a day, approximately 12 hours apart, for approximately 2 weeks.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of atopic dermatitis * good health with the exception of atopic dermatitis * percent body surface area minimum requirements exclusion criteria: * subjects who are pregnant, nursing, or planning a pregnancy within the study participation period. * subjects who have any systemic or dermatological disorders with the exception of atopic dermatitis

Keywords: atopic dermatitis
replicative stress in hair follicle stem cells and pathogeny of hidradenitis suppurativa

Conditions: Hidradenitis Suppurativa

Summary: hidradenitis suppurativa is a recurrent chronic inflammatory follicular occlusive disease affecting hair follicles. hs is notoriously difficult and challenging to treat with a high morbidity impact and could be classified as an unmet medical need with no efficient therapeutic options. objective: investigators previously showed that outer root sheath cells (ors) isolated from hair follicle of hs patients (hs-ors) have a pro-inflammatory phenotype and secrete spontaneously ip-10 and rantes. to identify the mechanisms involved in the pro-inflammatory phenotype of hs-ors, investigators performed a transcriptomic analysis in healthy and hs patients. this revealed: (i) an ifn signature, (i) a dysregulation of genes involved in cell proliferation and differentiation, and (iii) an upregulation of dna damage response and cell cycle g2/m checkpoint pathways in hs-ors. these findings support the notion that, in hs patients, a perturbation of hf-sc homeostasis leading to an increased proliferation induces a replicative stress and an accumulation of cytoplasmic ssdna, stimulating ifn synthesis through ifi16-sting pathway. interestingly, replicative stress in ors were present in some but not all patients with hidradenitis suppurativa. the goal of study is to determine replicative stress in ors in a large cohort of hs patients. method patients will be enrolled in the mondor dermatology department, during routine care. a dermatologist will check all inclusion and exclusion criteria with the technical support of a research technician of the henri mondor clinical investigation center. medical history, clinical data, comorbidities and concomitant therapies will be prospectively recorded in a dedicated case report form. skin biopsies will be performed in perilesional zone rich in hair follicles. mrna will be extracted from freshly isolated hair follicle cells and some slides will be prepared and stored at -80°c to perform immunohistochemistry analysis on freshly isolated hair follicle cells. pbmc and serum will be collected. all these biological samples will allow us to quantify the replicative stress in hs-ors of each patient, and to quantify several cytokine of interest : ifn de type 1, il-17, il-6, tnf-α, il-10 this study will allow investigators to evaluate the rate of patients with replicative stress in hair follicle stem cells in hidradenitis suppurativa. the investigator will also determine whether hf-sc replication stress correlates with clinical characteristics and/or with clinical course and/or comorbidities.


Eligibility criteria:
inclusion criteria: * patients referred to the consultation of dermatology of henri mondor hospital * diagnosis of hidradenitis suppurativa * age\> 18 y.o. * affiliation to a social security system exclusion criteria: * patient under tutorship or curatorship * breastfeeding or pregnant women * refusal to sign the consent letter * patients benefiting from state medical aid

Keywords: cytokine inflammation replicative stress hidradenitis suppurativa
effect of the erchonia® evrl otc™ for the relief of diabetic peripheral neuropathy foot pain

Conditions: Neuropathy

Summary: this study is to see if applying red and violet low-level laser light can help to reduce foot pain associated with diabetic peripheral neuropathy,

the purpose of this study is to determine whether low level laser therapy is effective in the reduction of foot pain associated with diabetic peripheral neuropathy, when used at home by non-medical professionals.

Eligibility criteria:
inclusion criteria: * previously diagnosed with diabetes-induced peripheral neuropathy by a qualified health physician. * over the age of 18 years of age * able to read and write english. * constant feet pain on-going over at least the past 3 months. * subject is willing and able to refrain from consuming any otc and/or prescription medications including muscle relaxants and/or herbal supplements and/or recreational and medical drugs including cannabis intended for the relief of pain and/or inflammation throughout the course of study participation, except for the study-specific pain relief medication of otc tylenol. * subject is willing and able to refrain from engaging in any non-study procedure therapies for the management of foot pain throughout the course of study participation, including conventional therapies such as physical therapy, occupational therapy and hot or cold packs, as well as alternative therapies such as chiropractic care and acupuncture. * self-reported foot pain on the numerical rating scale (nrs) is 50 or greater exclusion criteria: * pregnant or think you might be pregnant. * open wounds (sores, cuts, ulcers, etc) around the feet * cancerous growths around the feet
evaluation of efficiency of esophageal capsule endoscopy in the screening of patients with gastroesophageal reflux disease or dyspepsia as compared to upper endoscopy

Conditions: Gastroesophageal Reflux Disease; Dyspepsia

Summary: the exploration of evocative symptoms of esophageal reflux disease or dyspepsia is based on a relatively invasive endoscopic examination, often badly tolerated, and which, in france, is carried out in 50% of the cases under general anaesthesia. the development of a capsule endoscopy, of single use, of esophageal exploration (pillcam oeso), could allow a painless exploration of the oesophagus, without infectious risk.the aim of this study is to validate the information provided by the esophageal capsule endoscopy compared to upper endoscopy in the screening of patients with gastroesophageal reflux disease or dyspepsia . for that these patients, after being informed and to have given their signed assent, will initially have an exploration by esophageal capsule endoscopy and then, the very same day or within 3 days maximum, a upper endoscopy'. the information provided by the esophageal capsule endoscopy then by the upper endoscopy will be analyzed by investigators different. this study should make it possible to evaluate the parameters of specificity, sensitivity and predictive values of esophageal capsule endoscopy in this indication.


Eligibility criteria:
inclusion criteria: * patient age is 18 years or older * patient suffers from gastroesophageal reflux disease or dyspepsia, did not undergo previous upper endoscopy, with clinical indication to upper endoscopy,able to tolerate an upper endoscopy without general anesthesia * patient agrees and signs the informed consent form exclusion criteria: * dysphagia * known zenker's diverticulum * known or suspected intestinal obstruction. * cardiac pacemakers or other implanted electro medical devices. * female pregnant patient * upper endoscopy for control or recent upper endoscopy * chronic alcoholism defined by a daily consumption of alcohol over 80 g * severe hepatopathy * severe, primitive or secondary gastroparesis * known cancer * abnormalities of coagulation * incapacity to understand and sign a sensible consent of participation to the study

Keywords: gastroesophageal reflux dyspepsia esophageal capsule endoscopy
drainage of tuberculous pleural effusions

Conditions: Tuberculous Pleurisy

Summary: tuberculous (tb) pleurisy can cause clinical symptoms and pleural fibrosis with resultant residual pleural thickening (rpt). therapeutic thoracentesis or initial complete drainage in addition to anti-tb drugs have been tried to rapidly relieve dyspnea caused by effusion and to decrease the occurrence of rpt. however, contradictory results are reported without clear reasons. the researchers' hypothesis is that, in addition to anti-tb medications, early effective evacuation of inflammatory exudates with or without fibrinolytic agents may hasten resolution of pleural effusion, reduce the occurrence of rpt and finally improve long-term functional outcome in patients with tb pleurisy.


Eligibility criteria:
inclusion criteria: * diagnosis of tuberculous pleurisy exclusion criteria: * history of invasive procedures directed into the pleural cavity * recent severe trauma, hemorrhage, or stroke; bleeding disorder or anticoagulant therapy * use of streptokinase in the previous 2 years * lack of clinical symptoms caused by effusions

Keywords: loculated pleural effusion pigtail drainage pleural effusion pleural thickening tuberculosis
evidence based decision making: integrating clinical prediction rules

Conditions: Strep Pharyngitis; Pneumonia

Summary: clinical prediction rules (cprs) are frontline decision aids that help physicians make evidence-based, cost-effective decisions that benefit their patients. the aims of this project are to incorporate two well validated cprs (streptococcal pharyngitis prediction rule and the pneumonia clinical prediction rule) into an outpatient electronic medical record system (emr) and to perform a randomized controlled trial of the effectiveness of integrated cprs impact on doctor's behaviors (e.g. test ordering and medication prescribing).

clinical prediction rules (cprs) are frontline decision aids that help physicians make evidence-based, cost-effective decisions that benefit their patients. cprs are proven tools that translate evidence into practice, increase quality while reducing costs, and can be used by physicians in a wide variety of clinical settings, such as primary care offices, emergency rooms, and hospitals. while many cprs have been developed and validated over the years, health care providers have yet to incorporate them into everyday care. cprs aid providers in assessing the impact of individual components of a patient's history, physical examination, and basic lab results to estimate probability of disease or potential response to a treatment. prediction rules use data that is readily available at the time of a patient encounter and often reduce unnecessary treatments and diagnostic testing. cprs differ from reminder systems or alerts in that cprs pull in aspects of the history and physical exam and in an evidence based fashion estimate probabilities, prognosis, or make treatment recommendations. the goal of this study is to utilize patient electronic health records to incorporate cprs into the face-to-face patient encounter. we propose to select certain clinical situations where well-validated cprs are available and likely to be needed on a frequent basis. we will randomly assign an integrated cpr versus usual care into the point of care and evaluate the impact of this integration on doctor behavior and evidence-based decision making. mount sinai's division of general internal medicine (dgim) has significant experience with all aspects of cprs, including derivation, validation, implementation, and systematic review. furthermore, the division has developed an interactive web library of cprs for clinical use that is one of the most widely sites of its kind. we propose to collaborate with epic, one of the nation's largest and most respected electronic medical record (emr) companies, to integrate validated cprs into emrs and assess the impact on provider behavior and patient care.

Eligibility criteria:
inclusion criteria: * providers who are part of mount sinai's division of general internal medicine exclusion criteria: * not a provider at mount sinai's division of general internal medicine

Keywords: clinical prediction rules electronic health records walsh clinical prediction rule heckerling clinical prediction rule
a preoperative model to predict the lymphovascular invasion in pancreatic ductal adenocarcinoma

Conditions: Predictive Cancer Model; Pancreas Cancer

Summary: importance: lymphovascular invasion (lvi) is a poor prognosis pathologic feature in pancreatic ductal adenocarcinoma (pdac) patients. neoadjuvant therapy may bring survival benefits to these patients. objective: to construct a preoperative model which could predict lvi in pdac patients and further validate it in other cohorts. design, setting, and participants: patients from 3 three tertiary hospitals were included in this study. univariate and multivariate logistic regression analyses were conducted to define independent prediction factors of lvi. a nomogram was constructed based on the result of multivariate analysis.the predictive value of the model was assessed using receiver operating characteristic (roc) curves and the maximum youden index of the roc curve was defined as the cut-off point. the calibration plot was utilized to assess the concordance of the model. the decision curve analyses (dca) were applied to estimate the clinical benefit of using this model to predict lvi.


Eligibility criteria:
inclusion criteria: * patients who were pathologically diagnosed as pdac and received curative surgery. exclusion criteria: * patients with distant metastasis; patients who received neoadjuvant therapy; patients with a survival time of less than 1 month.
safety and efficacy of sof/vel/vox fdc for 12 weeks and sof/vel for 12 weeks in daa-experienced adults with chronic hcv infection who have not received an ns5a inhibitor

Conditions: Hepatitis C Virus Infection

Summary: the primary objectives of the study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (vosevi®; sof/vel/vox) fixed-dose combination (fdc) for 12 weeks and of sofosbuvir/velpatasvir (epclusa®; sof/vel) fdc for 12 weeks in direct-acting antiviral (daa)-experienced adults with chronic hepatitis c virus (hcv) infection with or without cirrhosis who have not received prior treatment with a regimen containing an inhibitor of the hcv ns5a protein.


Eligibility criteria:
key inclusion criteria: * willing and able to provide written informed consent * hcv rna ≥ 10\^4 iu/ml at screening * chronic hcv infection (≥ 6 months) * treatment experienced with a direct acting antiviral medication not including a ns5a inhibitor for hcv * use of protocol specified methods of contraception key exclusion criteria: * current or prior history of clinically significant illness that may interfere with participation in the study * screening ecg with clinically significant abnormalities * laboratory results outside of acceptable ranges at screening * pregnant or nursing female * chronic liver disease not caused by hcv * infection with hepatitis b virus (hbv) or human immunodeficiency virus (hiv) note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: chronic